Sensei Biotherapeutics Stock Today
| SNSE Stock | USD 0.47 0.01 2.08% |
Performance1 of 100
| Odds Of DistressOver 84
|
Sensei Biotherapeutics is trading at 0.47 as of the 30th of January 2025, a 2.08 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.46. Sensei Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 30th of January 2025. Click here to learn more.
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. The company has 25.15 M outstanding shares of which 757.82 K shares are at this time shorted by private and institutional investors with about 0.29 trading days to cover. More on Sensei Biotherapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Sensei Stock Highlights
| CEO President | John MBA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Sensei Biotherapeutics (SNSE) is traded on NASDAQ Exchange in USA. It is located in 1405 Research Boulevard, Rockville, MD, United States, 20850 and employs 28 people. Sensei Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.05 M. Sensei Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.15 M outstanding shares of which 757.82 K shares are at this time shorted by private and institutional investors with about 0.29 trading days to cover.
Sensei Biotherapeutics currently holds about 123.71 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sensei Biotherapeutics Probability Of Bankruptcy
Ownership AllocationSensei Biotherapeutics shows a total of 25.15 Million outstanding shares. Sensei Biotherapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sensei Ownership Details
Sensei Biotherapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Sensei Biotherapeutics market risk premium is the additional return an investor will receive from holding Sensei Biotherapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0211 | |||
| Jensen Alpha | 0.0625 | |||
| Total Risk Alpha | (0.51) | |||
| Sortino Ratio | (0) |
Sensei Stock Against Markets
Sensei Biotherapeutics Corporate Management
| Edward Horst | Chief Officer | Profile | |
| Christopher JD | VP Counsel | Profile | |
| Elisabeth Colunio | VP HR | Profile | |
| Lora Pike | Vice Communications | Profile | |
| Steven Fuller | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Erin Colgan | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.